The disclosure provides methods and compositions for the treatment of hidradenitis suppurativa. The disclosure describes the methods and uses for treating hidradenitis suppurativa in a subject using a TNFa inhibitor, such as a human TNFa antibody, or an antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNPa inhibitor for treating hidradenitis suppurativa in a subject.